Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[EX Q]: "Bounciest Democrat on November's statewide ballot? It might be Hank Gilbert, making his second hard charge for state agriculture commissioner versus Todd Staples, the Republican who topped him four years ago. Gilbert, ever prowling for issues, recently trumpeted that the Texas Department of Agriculture is looking at buying thousands of stress balls -- squeezable toys. He said in a Sept. 24 press release: ""Make no mistake, Texans love their balls: footballs, baseballs, basketballs, and soccer balls. But 300,000 stress balls? It seems a little extreme, but that's the quantity of grape, barbell, and book-shaped polyurethane stress balls the Texas Department of Agriculture could be spending taxpayer dollars on...""  Really? To our inquiry, Gilbert's campaign provided Web links to the agriculture agency's June request for bids as well as a September post on a state website indicating that a $99,000 contract to provide promotional materials was awarded to a Massachusetts company, Oceans Promotions. We downloaded the June 29 bid-request package from a site for state requisitions overseen by the state comptroller's office. The package shows the department was seeking bids to provide up to 300,000 stress ""relievers,"" which we're guessing are not balls because they're not round. Precisely, the package says, the agency sought bids to make ""promotional items with logo imprints to follow through on (the) TDA Food and Nutrition Texans Bring It Campaign,"" with the items to include grape-shaped stress relievers with ""Texans Bring It"" written on them or ""Eating Right,"" which would be made of polyurethane and be two inches high by three inches wide. The package says a second set of stress relievers, each one called ""Dumbbell,"" would be imprinted ""Texans Bring It"" and ""Exercise"" and be five inches high by 1.8 inches in diameter. A third stress reliever would be imprinted ""Book"" and ""Texans Bring It,"" according to the bid package, while other promotional items would include pencils, buttons and bumperstickers. The package says the bids were sought for various quantities, starting from 2,500 and topping out at 100,000 each. It electronically links to a Branders.com site showing what the agency wanted the stress relievers to look like (our interpretation: bunches of purple grapes). Is all this a real deal? To our inquiry, Bryan Black, Staples' spokesman, replied via e-mail: ""An invitation for bid was issued for these federally funded educational items to reduce the $5.8 billion avoidable health care expenditures, paid by taxpayers, associated with overweight and obesity health problems."" We followed up with Black, asking if it's accurate to conclude that up to 300,000 of the stress relievers are being purchased. We also wondered why the purchase was being made. Black said he'd limit his comment to his e-mailed statement. Surely the agency would pipe up if Gilbert got its purchase plans wrong."
[EX A]: Hank Gilbert Says the Texas Department of Agriculture seeks to purchase up to 300,000 promotional stress balls.

[EX Q]: Low doses of the drug FTY720, also called fingolimod, given  to mice once a day for three days eliminated an infection by a  virus that can cause meningitis, an inflammation of the  membranes surrounding the brain and spinal cord. The findings suggest the drug, which boosted anti-viral  immune responses in the mice, may be useful against viruses  that cause high-level, long-lasting infections in people such  as hepatitis C and HIV, the researchers said. Microbiologist and immunologist John Altman of Emory  University in Atlanta, who led the study, said the researchers  plan to assess the effects of the drug on other viruses  including the monkey version of the AIDS virus. Altman, whose findings were published in the journal  Nature, expressed cautious optimism that the drug might work  against certain chronic viral infections in people. “We think it’s crucial that we do experiments to check it  out,” Altman said in a telephone interview. The drug is generally considered to be an immunosuppressant  that works to restrain the body’s natural defenses. That could be helpful in multiple sclerosis, an autoimmune  disease in which the immune system attacks body parts as if  they were foreign invaders. But one effect of the drug seems to facilitate the immune  response, the researchers said. FTY720 among other things traps  white blood cells — key soldiers in the immune system’s fight  against infections — in the lymph nodes, Altman said. With viral infections, the lymph nodes are where the immune  response can get primed and started, Altman said. Some viruses  replicate themselves at high levels in lymph nodes, including  the human immunodeficiency virus that causes AIDS. They tested the drug against a mouse virus called  lymphocytic choriomeningitis, which causes chronic infections  by escaping immune responses. “In the absence of treatment (with FTY720) we have an  exhausted immune response. In the presence of treatment, we  regain a robust cellular immune response,” Altman said. Swiss drug maker Novartis said in June two multiple  sclerosis patients taking FTY720 in clinical trials had  problems with infections and one died, but the role of the drug  in the cases was unclear. Novartis plans at the end of 2009 to seek approval by the  European Union for FTY720 to treat MS, spokeswoman Valerie Tate  said by e-mail. The drug is currently in late-stage trials. Altman said his study was backed by the U.S. government’s  National Institutes of Health and was not funded by Novartis.
[EX A]: MS drug may work against viral infection: study.

[EX Q]: "The cost of the drugs was not mentioned. And the possible cost-effectiveness ramifications of the research were not mentioned. As is often the case with 70% of the stories we review, cost just doesn’t seem to matter. But we all know it does. The benefits are given only in relative, not absolute terms. See our primer on this topic. So when the story says ""24 percent lower incidence of dementia"" or ""The risk was 19 percent lower"" or ""The risk was nearly halved"" – readers need to know 24% of what? 19% of what? Half of what? One harm was mentioned – ""There are potential hazards, such as too-low blood pressure that can lead to damaging falls."" That’s an incomplete listing, but we’ll give the story the benefit of the doubt in at least nodding in the direction of potential harms. The story did state:  ""The new report describes an observational study, one that lacks the strict controls that are needed for convincing proof."" And it further quoted the lead researcher saying, ""Any study like this is hypothesis-generating. You only know for sure when you have done clinical prospective trials."" So we’ll give it a satisfactory grade. But we do with mixed feelings. That’s because we’re troubled when the story talks about ""a small but protective effect "" and uses active verbs to say the drugs ""may stave off dementia."" That is terribly misleading to the reader. ""Protective effect"" when you state in the story this is not convincing proof of cause and effect? Blogger Emlly DeVoto wrote about the problem with causal language used in a Guardian article on the same study. There is no overt disease-mongering of dementia in the story. The story did quote one independent expert who injected a cautionary note – in addition to the lead researcher. The story did note other observational studies that have ""implicated various molecules"" in dementia. We’ll again give the story the benefit of the doubt on this criterion. Although never explicity stated, the widespread availability of angiotensin inhibiting drugs can be inferred from the story. The story doesn’t frame the new study into the context of past research linking high blood pressure to dementia. There’s no evidence that the story relied on a news release."
[EX A]:
Some Blood Pressure Drugs May Stave Off Dementia